The highly anticipated kick-off meeting of the innovative project, IMPACT-AML, took place in the town of Cesenatico, Italy. The meeting spanned two days, from the 6th to the 7th of July, gathering experts and participants from across Europe, all committed to tackling the challenges of relapse or refractory acute myeloid leukemia (R/R AML).
The proceedings were inaugurated by the mayors of Cesenatico, Matteo Gozzoli, and Meldola, Roberto Cavallucci, emphasizing the significance of the project's impact on both local and global communities.
The meeting showcased the different work packages of IMPACT-AML, providing a comprehensive overview of the strategies and efforts that will be employed to achieve the project's ambitious goals.
IMPACT-AML's primary objectives were unveiled during the meeting, each aimed at revolutionizing the approach to R/R AML treatment and ensuring inclusivity and accessibility. The three main objectives are as follows:
ERN-Eurobloodnet plays a pivotal role in the IMPACT-AML project by providing a robust platform for seamless data collection and ensuring interoperability with other initiatives under its umbrella. By harnessing the resources and expertise of ERN-Eurobloodnet, IMPACT-AML gains the necessary support to optimize data sharing, fostering collaborative research efforts that hold the potential to transform the landscape of acute myeloid leukemia treatment.
With an enthusiastic and diverse group of participants, the IMPACT-AML kick-off meeting set the stage for a promising journey towards improving the outcomes and quality of life for patients facing the challenges of R/R AML. This project holds the potential to transform the landscape of AML treatment, breaking down barriers and uniting experts across borders in the pursuit of a common goal.